olmutinib

Ligand id: 9196

Name: olmutinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 110.86
Molecular weight 486.18
XLogP 4.56
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Approved drug? Yes (South Korea (2016))
IUPAC Name
N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
International Nonproprietary Names
INN number INN
10093 olmutinib
Synonyms
BI-1482694 | Example 1 [US20130116213] | HM-61713 | HM61713
Database Links
CAS Registry No. 1353550-13-6 (source: WHO INN record)
PubChem CID 54758501
Search Google for chemical match using the InChIKey FDMQDKQUTRLUBU-UHFFFAOYSA-N
Search Google for chemicals with the same backbone FDMQDKQUTRLUBU
Search PubMed clinical trials olmutinib
Search PubMed titles olmutinib
Search PubMed titles/abstracts olmutinib
Search UniChem for chemical match using the InChIKey FDMQDKQUTRLUBU-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone FDMQDKQUTRLUBU
Comments
Olmutinib from Hanmi Pharmaceutical, approved in South Korea for lung cancer, targets EGFR mutations selectively over wild-type. While reported as a covalent inhibitor there is no published data. It is claimed in patent WO2011162515 [1]. Full text descriptions and structure images are available in US20130116213 [3], where it is identified as Example 1 (N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide). Note we updated this entry in Nov 2016 with the removal of the incorrect synonyms HM-71224 and LY3337641 which refer to a blinded Hanmi BTK inhibitor [4].